An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far

References

• RahoG, KolevaDM, GarattiniL, NaldiL. The burden of moderate to severe psoriasis: an overview. PharmacoEconomics. 2012;30(11):1005–1013. doi:10.2165/11591580-000000000-0000022994598
   PubMed Web of Science ®Google Scholar
• AlinaghiF, CalovM, KristensenLE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19.29928910
   PubMed Web of Science ®Google Scholar
• RitchlinCT, ColbertRA, GladmanDD. Psoriatic arthritis. Longo DL, editor. N Engl J Med. 2017;376(10):957–970. doi:10.1056/NEJMra150555728273019
   PubMed Web of Science ®Google Scholar
• GossecL, BaraliakosX, KerschbaumerA, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi:10.1136/annrheumdis-2020-21715932434812
   PubMed Web of Science ®Google Scholar
• OrrC, VealeDJ. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis? Ann Rheum Dis. 2014;73(6):951–953. doi:10.1136/annrheumdis-2013-20493424790066
   PubMed Web of Science ®Google Scholar
• ReisJ, VenderR, TorresT. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391–399. doi:10.1007/s40259-019-00361-631172372
   PubMed Web of Science ®Google Scholar
• TaamsLS, SteelKJA, SrenathanU, BurnsLA, KirkhamBW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14(8):453–466.30006601
   PubMed Web of Science ®Google Scholar
• AdamsR, MaroofA, BakerT, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.0189432973785
   PubMed Web of Science ®Google Scholar
• GlattS, BaetenD, BakerT, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532. doi:10.1136/annrheumdis-2017-21212729275332
   PubMed Web of Science ®Google Scholar
• RitchlinCT, KavanaughA, MerolaJF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440. doi:10.1016/S0140-6736(19)33161-732035552
   PubMed Web of Science ®Google Scholar
• BlauveltA, ChiricozziA. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinic Rev Allerg Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• WadeSM, CanavanM, McGarryT, et al. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. Ann Rheum Dis. 2019;78(3):350–354. doi:10.1136/annrheumdis-2018-21413830626658
   PubMed Web of Science ®Google Scholar
• MenonB, GullickNJ, WalterGJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272–1281. doi:10.1002/art.3837624470327
   PubMed Web of Science ®Google Scholar
• ChowdhuryAC, ChaurasiaS, MishraSK, AggarwalA, MisraR. Misra R. IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clin Immunol. 2017;183:207–212. doi:10.1016/j.clim.2017.03.01628390966
   PubMed Web of Science ®Google Scholar
• ZabaLC, Suárez-FariñasM, Fuentes-DuculanJ, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124(5):1022–1030.e395. doi:10.1016/j.jaci.2009.08.04619895991
   PubMed Web of Science ®Google Scholar
• WatanabeH, KawaguchiM, FujishimaS, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Clin Investig Dermatol. 2009;129(3):650–656. doi:10.1038/jid.2008.294
   Google Scholar
• CuthbertRJ, WatadA, FragkakisEM, et al. Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78(11):1559. doi:10.1136/annrheumdis-2019-21521031530557
   PubMed Web of Science ®Google Scholar
• ShahM, MaroofA, GikasP, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020;6(2):e001306. doi:10.1136/rmdopen-2020-00130632723833
   PubMed Web of Science ®Google Scholar
• BurnsLA, MaroofA, MarshallD, et al. Presence, function, and regulation of IL‐17F‐expressing human CD4 + T cells. Eur J Immunol. 2020;50(4):568–580. doi:10.1002/eji.20194813831850514
   PubMed Web of Science ®Google Scholar
• KolbingerF, LoescheC, ValentinM-A, et al. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923–932.e8. doi:10.1016/j.jaci.2016.06.03827502297
   PubMed Web of Science ®Google Scholar
• van BaarsenLG, LebreMC, van der CoelenD, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426. doi:10.1186/s13075-014-0426-z25146432
   PubMed Web of Science ®Google Scholar
• GoepfertA, LehmannS, BlankJ, KolbingerF, RondeauJ-M. Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling. Immunity. 2020;52(3):499–512.e5. doi:10.1016/j.immuni.2020.02.00432187518
   PubMed Web of Science ®Google Scholar
• GlattS, HelmerE, HaierB, et al. First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. doi:10.1111/bcp.1318527859546
   PubMed Web of Science ®Google Scholar
• DeodharA, GossecL, MeasePJ, et al. Bimekizumab treatment is associated with improvements in back pain and fatigue in patients with active psoriatic arthritis: 48-week results from a Phase 2b study. ACR Meeting Abstracts [Internet]; [ cited January 3, 2021]. Available from: https://acrabstracts.org/abstract/bimekizumab-treatment-is-associated-with-improvements-in-back-pain-and-fatigue-in-patients-with-active-psoriatic-arthritis-48-week-results-from-a-phase-2b-study/. Accessed 225, 2021.
   Google Scholar
• GossecL, MeasePJ, GottliebAB, et al. AB0778 Association between patient-reported outcomes and disease activity in bimekizumab-treated patients with psoriatic arthritis. Ann Rheum Dis. 2020;79(Suppl 1):1687. doi:10.1136/annrheumdis-2020-eular.4204
   Web of Science ®Google Scholar
• GossecL, MeaseP, GottliebA, et al. Bimekizumab improves patient-reported outcomes in psoriatic arthritis: 48-week results from a phase 2b study and association between patient-reported outcomes and disease activity. ACR Meeting Abstracts [Internet]; [ cited January 3, 2021]. Available from: https://acrabstracts.org/abstract/bimekizumab-improves-patient-reported-outcomes-in-psoriatic-arthritis-48-week-results-from-a-phase-2b-study-and-association-between-patient-reported-outcomes-and-disease-activity/. Accessed 225, 2021.
   Google Scholar
• McinnesI, MerolaJF, MeasePJ, et al. SAT0403 efficacy and safety of 108 weeks’ bimekizumab treatment in patients with psoriatic arthritis: interim results from a phase 2 open-label extension studY. Ann Rheum Dis. 2020;79(Suppl 1):1153. doi:10.1136/annrheumdis-2020-eular.1850
   Web of Science ®Google Scholar
• MerolaJ, BehrensF, KivitzA, et al. Bimekizumab maintenance of response in patients with psoriatic arthritis: 2-year results from a Phase 2b dose-ranging study and its open-label extension. ACR Meeting Abstracts [Internet]; [ cited January 3, 2021]. Available from: https://acrabstracts.org/abstract/bimekizumab-maintenance-of-response-in-patients-with-psoriatic-arthritis-2-year-results-from-a-phase-2b-dose-ranging-study-and-its-open-label-extension/. Accessed 225, 2021.
   Google Scholar
• BenfaremoD, PaciV, LuchettiMM, GabrielliA. Novel therapeutic approaches and treatment targets for psoriatic arthritis. CPB [Internet]; 9 28, 2020 [ cited January 3, 2021]:21. Available from: https://www.eurekaselect.com/186326/article. Accessed 225, 2021.
   Google Scholar
• COSENTYX (secukinumab) injection, Label changes, FDA [Internet]; [ cited January 1, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf. Accessed 225, 2021
   Google Scholar
• TALTZ (ixekizumab) injection, SC, Label changes, FDA [Internet]; [ cited January 1, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf. Accessed 225, 2021.
   Google Scholar
• TongZ, YangXO, YanH, et al. A protective role by interleukin-17f in colon tumorigenesis. Katoh M, editor. PLoS One. 2012;7(4):e34959. doi:10.1371/journal.pone.003495922509371
   PubMed Web of Science ®Google Scholar
• QianX, ChenH, WuX, HuL, HuangQ, JinY. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 2017;89:34–44. doi:10.1016/j.cyto.2015.09.01126883678
   PubMed Web of Science ®Google Scholar
• McInnesIB, BehrensF, MeasePJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496–1505. doi:10.1016/S0140-6736(20)30564-X32386593
   PubMed Web of Science ®Google Scholar
• MeasePJ, SmolenJS, BehrensF, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131. doi:10.1136/annrheumdis-2019-21538631563894
   PubMed Web of Science ®Google Scholar
• ReichK, PappKA, BlauveltA, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-233549193
   PubMed Web of Science ®Google Scholar
• WarrenR, BlauveltA, BagelJ, et al. Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: results from a multicenter, randomized, double-blinded active comparator-controlled phase 3 trial (Be Sure). J Skin. 2021;5(1):s15. doi:10.25251/skin.5.supp.15
   Google Scholar
• UCB Press Release – Bimekizumab superior to Cosentix in achieving complete psoriasis skin clearance [Internet]; [ cited January 1, 2020]. Available from: https://www.ucb.com/_up/ucb_com_presscenter/documents/b611cc6eeb06894e.pdf. Accessed 225, 2021
   Google Scholar